Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk Withholding Tresiba From German HTA Process

This article was originally published in The Pink Sheet Daily

Executive Summary

Withholding Tresiba from Europe’s biggest drug market seems counterintuitive in view of the ultra-long-acting insulin’s spreading acceptance elsewhere. But in doing so, Novo avoids having Germany’s reimbursement authorities questioning its benefits and demanding a price cut.

You may also be interested in...

Novo Nordisk Narrows Saxenda’s Positioning, Targets Seriously Ill Patients

The Danish diabetes specialist is preparing to diversify into obesity with the first launches of Saxenda expected in the first half of 2015. Competition is expected to increases for GLP-1 market leader Victoza but Novo Nordisk also expects a more benign U.S. pricing environment during the year.

Transparency Issues Floor Novo Nordisk's Tresiba At IQWiG

IQWiG has said that Novo Nordisk's refusal to make public part of its dossier for its diabetes therapy Tresiba represents a lack of transparency and makes the drug impossible to recommend.

Novo Nordisk CEO To Focus On U.S. As COO Schultz Gains Extra Duties

The sharing of executive responsibilities with Kare Schultz frees up CEO Lars Sorensen to focus on key growth markets, as Novo Nordisk faces growing competitive pressures from generics, new diabetes market entrants and a tougher pricing environment.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts